JP2010512315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512315A5 JP2010512315A5 JP2009540288A JP2009540288A JP2010512315A5 JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5 JP 2009540288 A JP2009540288 A JP 2009540288A JP 2009540288 A JP2009540288 A JP 2009540288A JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnα
- inducible
- activity
- expression profile
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 21
- 230000000694 effects Effects 0.000 claims 11
- 239000003550 marker Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims 3
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 claims 3
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims 3
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 claims 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims 3
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 3
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 3
- 101000880044 Homo sapiens SLIT-ROBO Rho GTPase-activating protein 3 Proteins 0.000 claims 3
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims 3
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 claims 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims 3
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 3
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 3
- 102100037372 SLIT-ROBO Rho GTPase-activating protein 2 Human genes 0.000 claims 3
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims 3
- 102100039488 XIAP-associated factor 1 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 239000003124 biologic agent Substances 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87300806P | 2006-12-06 | 2006-12-06 | |
| US90776207P | 2007-04-16 | 2007-04-16 | |
| US90776707P | 2007-04-16 | 2007-04-16 | |
| US92422007P | 2007-05-03 | 2007-05-03 | |
| US92421907P | 2007-05-03 | 2007-05-03 | |
| US92458407P | 2007-05-21 | 2007-05-21 | |
| US96018707P | 2007-09-19 | 2007-09-19 | |
| US99617407P | 2007-11-05 | 2007-11-05 | |
| US99617607P | 2007-11-05 | 2007-11-05 | |
| US99621907P | 2007-11-06 | 2007-11-06 | |
| US99682007P | 2007-12-06 | 2007-12-06 | |
| PCT/US2007/024947 WO2008070137A2 (en) | 2006-12-06 | 2007-12-06 | Interferon alpha-induced pharmacodynamic markers |
| PCT/US2007/024941 WO2008070135A2 (en) | 2006-12-06 | 2007-12-06 | Methods of treating systemic lupus erythematosus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183939A Division JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512315A JP2010512315A (ja) | 2010-04-22 |
| JP2010512315A5 true JP2010512315A5 (enExample) | 2011-01-20 |
Family
ID=39492862
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540288A Pending JP2010512315A (ja) | 2006-12-06 | 2007-12-06 | インターフェロンα誘導性薬力学的マーカー |
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20100143372A1 (enExample) |
| EP (3) | EP2712930A3 (enExample) |
| JP (4) | JP2010512315A (enExample) |
| KR (2) | KR20090088932A (enExample) |
| AU (2) | AU2007327995B2 (enExample) |
| BR (2) | BRPI0720035A2 (enExample) |
| CA (2) | CA2670897A1 (enExample) |
| MX (1) | MX2009005787A (enExample) |
| RU (2) | RU2527068C2 (enExample) |
| WO (2) | WO2008070135A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| WO2008137838A2 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| CA2692784C (en) * | 2007-07-12 | 2018-10-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for diagnosing and assessing inflammatory myopathies |
| AU2008324800B2 (en) | 2007-11-05 | 2014-03-27 | Astrazeneca Ab | Methods of treating scleroderma |
| WO2009100342A2 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Disease markers and uses thereof |
| SMT201700063T1 (it) * | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| WO2011132086A2 (en) | 2010-04-21 | 2011-10-27 | MeMed Diagnostics, Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| WO2012088305A1 (en) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| WO2012149228A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| GB201115665D0 (en) * | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| AU2013217935B2 (en) | 2012-02-09 | 2018-05-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2013173266A1 (en) | 2012-05-17 | 2013-11-21 | The Johns Hopkins University | Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy |
| CN104603152A (zh) * | 2012-06-13 | 2015-05-06 | 米迪缪尼有限公司 | 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 |
| US20140156297A1 (en) * | 2012-08-03 | 2014-06-05 | Axelacare Holdings, Inc. | Computer program, method, and system for pharmacist-assisted treatment of patients |
| US20140039907A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for collecting patient data with a portable electronic device |
| US20140275257A1 (en) * | 2013-03-14 | 2014-09-18 | Foundation for the State University of New York | N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus |
| RU2730836C2 (ru) | 2014-08-14 | 2020-08-26 | Мемед Диагностикс Лтд. | Вычислительный анализ биологических данных с применением многообразия и гиперплоскости |
| CN105420347A (zh) * | 2014-08-21 | 2016-03-23 | 南京大学医学院附属鼓楼医院 | 一种用于系统性红斑狼疮的基因诊断试剂盒 |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| EP3230740B1 (en) | 2014-12-11 | 2025-05-21 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| WO2017149547A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Analyzing rna for diagnosing infection type |
| WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018011796A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| US20200008916A1 (en) * | 2016-12-16 | 2020-01-09 | The Penn State Research Foundation | Methods for improved reproductive management of ruminant ungulates |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| US11926664B2 (en) | 2017-07-25 | 2024-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3117102A1 (en) * | 2018-10-26 | 2020-04-30 | Janssen Biotech, Inc. | Type i interferon signatures and methods of use |
| CA3121247A1 (en) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| EP3924383A1 (en) | 2019-02-15 | 2021-12-22 | Astrazeneca AB | Type i interferon-mediated disorders |
| US12011284B2 (en) * | 2020-05-19 | 2024-06-18 | Peachy Corp. | Systems and methods for preventing and treating wrinkles |
| KR102429261B1 (ko) | 2020-08-25 | 2022-08-03 | 충북대학교 산학협력단 | 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커 |
| JP2023544351A (ja) * | 2020-10-02 | 2023-10-23 | セルジーン コーポレーション | 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用 |
| SMT202300382T1 (it) | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
| US11753644B2 (en) | 2021-06-18 | 2023-09-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing IFNAR1 expression |
| FR3138815A1 (fr) * | 2022-08-12 | 2024-02-16 | bioMérieux | Détermination de la nature virale ou bactérienne d’une infection |
| CN117305441B (zh) * | 2023-10-13 | 2025-04-08 | 福建农林大学 | 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法 |
| WO2025213238A1 (en) * | 2024-04-12 | 2025-10-16 | HaemaLogiX Ltd | Anti-kma antibody formulations |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| ATE78262T1 (de) | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| US6905587B2 (en) * | 1996-03-22 | 2005-06-14 | Ronald Redline | Method for enhancing the solderability of a surface |
| JP2002506436A (ja) | 1997-06-13 | 2002-02-26 | ザ ジョンズ ホプキンス ユニバーシティー | 治療用ナノスフェア |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20050008683A1 (en) * | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| AU2002365514A1 (en) * | 2001-11-30 | 2003-06-10 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| DK1569696T3 (da) * | 2002-11-21 | 2010-11-15 | Bayhill Therapeutics Inc | Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme |
| AU2004271200A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| PT2418220T (pt) * | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| ES2643237T3 (es) * | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| US7833795B2 (en) * | 2004-08-24 | 2010-11-16 | The Trustees Of The University Of Pennsylvania | Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors |
| US7571055B2 (en) * | 2004-10-13 | 2009-08-04 | Regents Of The University Of Minnesota | Systemic lupus erythematosus |
| WO2008021976A2 (en) * | 2006-08-09 | 2008-02-21 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| EP1851248B1 (en) * | 2005-02-10 | 2016-08-10 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US20070117105A1 (en) * | 2005-05-12 | 2007-05-24 | Crow Mary K | Interferon assay |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| ES2432026T3 (es) * | 2005-08-05 | 2013-11-29 | Genentech, Inc. | Métodos y composiciones para detectar trastornos autoinmunes |
| US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
| KR20080074120A (ko) * | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| KR101540823B1 (ko) * | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| SMT201700063T1 (it) * | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
-
2007
- 2007-12-06 WO PCT/US2007/024941 patent/WO2008070135A2/en not_active Ceased
- 2007-12-06 WO PCT/US2007/024947 patent/WO2008070137A2/en not_active Ceased
- 2007-12-06 CA CA002670897A patent/CA2670897A1/en not_active Abandoned
- 2007-12-06 KR KR1020097013891A patent/KR20090088932A/ko not_active Ceased
- 2007-12-06 MX MX2009005787A patent/MX2009005787A/es active IP Right Grant
- 2007-12-06 BR BRPI0720035-8A patent/BRPI0720035A2/pt active Search and Examination
- 2007-12-06 EP EP13179923.1A patent/EP2712930A3/en not_active Withdrawn
- 2007-12-06 BR BRPI0719912-0A2A patent/BRPI0719912A2/pt not_active IP Right Cessation
- 2007-12-06 CA CA002670594A patent/CA2670594A1/en not_active Abandoned
- 2007-12-06 JP JP2009540288A patent/JP2010512315A/ja active Pending
- 2007-12-06 AU AU2007327995A patent/AU2007327995B2/en not_active Ceased
- 2007-12-06 EP EP07867634A patent/EP2073844A4/en not_active Ceased
- 2007-12-06 US US12/517,333 patent/US20100143372A1/en not_active Abandoned
- 2007-12-06 RU RU2009125616/10A patent/RU2527068C2/ru not_active IP Right Cessation
- 2007-12-06 JP JP2009540285A patent/JP2010512313A/ja active Pending
- 2007-12-06 US US12/517,334 patent/US20100143373A1/en not_active Abandoned
- 2007-12-06 AU AU2007327993A patent/AU2007327993B2/en not_active Ceased
- 2007-12-06 EP EP07867637A patent/EP2077858A4/en not_active Ceased
- 2007-12-06 KR KR1020097013872A patent/KR101532797B1/ko not_active Expired - Fee Related
-
2013
- 2013-09-05 JP JP2013183939A patent/JP2014014370A/ja active Pending
- 2013-09-19 JP JP2013193959A patent/JP2014040430A/ja active Pending
-
2014
- 2014-07-03 RU RU2014127178A patent/RU2014127178A/ru not_active Application Discontinuation
- 2014-07-14 US US14/330,609 patent/US20150044222A1/en not_active Abandoned
-
2015
- 2015-01-27 US US14/606,832 patent/US20150147336A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/290,925 patent/US20170121771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010527917A5 (enExample) | ||
| Powell et al. | Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response | |
| Ouyang et al. | Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis | |
| Sypabekova et al. | Electrochemical aptasensor using optimized surface chemistry for the detection of Mycobacterium tuberculosis secreted protein MPT64 in human serum | |
| Camela et al. | Towards personalized medicine in psoriasis: current progress | |
| Conti et al. | Biomarkers to personalize the treatment of rheumatoid arthritis: focus on autoantibodies and pharmacogenetics | |
| RU2014127178A (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006 | |
| An et al. | From moderately severe to severe hypertriglyceridemia induced acute pancreatitis: circulating miRNAs play role as potential biomarkers | |
| WO2016062101A1 (zh) | 检测ndm-1的修饰电极及其制备方法和应用 | |
| RU2010144502A (ru) | Композиции и способы для лечения и диагностики астмы | |
| NZ590988A (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders | |
| Qasem et al. | Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease | |
| Cheleschi et al. | Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study | |
| JP2013178260A5 (enExample) | ||
| Ravi et al. | A GMR-based assay for quantification of the human response to influenza | |
| WO2007124309A3 (en) | Methods for detecting mutations in jak2 nucleic acid | |
| Kadasah et al. | Tumor necrosis factor-α and-β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia | |
| Backes et al. | Influence of next-generation sequencing and storage conditions on miRNA patterns generated from PAXgene blood | |
| Liu et al. | Functional effect of polymorphisms in the promoter of TNFAIP3 (A20) in acute pancreatitis in the Han Chinese population | |
| Hussain et al. | CCL2/MCP-I genotype-phenotype relationship in latent tuberculosis infection | |
| Sun et al. | Downregulation of microRNA‐101‐3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9 | |
| Mahmood et al. | The pncA gene mutations of Mycobacterium tuberculosis in multidrug‐resistant tuberculosis | |
| CN103820545B (zh) | 用于检测人abcg2基因突变的探针、引物及试剂盒 | |
| CN104120172B (zh) | 精神分裂症的基因标志物及其使用方法和应用 | |
| Moraes Holst et al. | Downregulated mucosal autophagy, alpha kinase-1 and IL-17 signaling pathways in active and quiescent ulcerative colitis |